Novartis AG vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Novartis AG trades at $153.04 (market cap $295.37B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.01. The key difference: Novartis AG pays a 3.07% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | QQQE | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $122.72 |
52-Week Low | $119.31 | $96.06 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →